Young Hee Ko, PhD - Our founder, CEO and a world-leading scientist, who discovered the potential of 3-Bromopyruvate (3-BP) for treating cancer in 2000 at Johns Hopkins University, has harnessed the power of 3-BP into a proprietary formulation and administration protocols to treat cancer.

​

As a result, in January of 2023, PrimoCure Pharma was granted an FDA Investigational New Drug (IND) approval to utilize KAT 3-BP in a 3-cohort, phase I/II(a) clinical trial for pancreatic cancer.